$6.440
+0.020 (+0.31%)Al cierre
Noticias de LFCR
Eventos de LFCR
Barrington Downgrades Lifecore to Market Perform
Barrington downgraded Lifecore to Market Perform from Outperform after the company agreed to be acquired by private equity firm Webster Equity Partners for $6.28 per share in cash at closing plus one non-tradable contingent value right per share.
Craig-Hallum Downgrades Lifecore to Hold with $6.28 Price Target
Craig-Hallum analyst Matthew Hewitt downgraded Lifecore to Hold from Buy with a $6.28 price target after the company agreed to be acquired by private equity firm Webster Equity Partners for $6.28 per share in cash at closing plus one non-tradable contingent value right per share.
William Blair Downgrades Lifecore to Market Perform
William Blair analyst Jared Haase downgraded Lifecore to Market Perform from Outperform after the company announced that it has entered into a definitive agreement to be acquired by private equity firm Webster Equity Partners in a transaction valued up to $663.7M, including $6.28 per share in cash at closing plus one non-tradable contingent value right per share.
Lifecore Biomedical Acquired by Webster Equity Partners in $663.7M Deal
Lifecore Biomedical announced that it has entered into a definitive agreement to be acquired by Webster Equity Partners in a transaction valued at up to $663.7M, assuming full achievement of certain performance milestones. Under the terms of the agreement, an entity affiliated with Webster Equity Partners will acquire all outstanding Lifecore common stock for $6.28 per share in cash at closing plus one non-tradable contingent value right per share. The holders of the Lifecore Series A Preferred Stock will be entitled to a payment in cash at closing equal to the "Conversion Amount" as defined in the Certificate of Designations relating to the Series A Preferred Stock as of the closing date, plus one non-tradable CVR per share of common stock into which the Series A Preferred Stock is convertible as of closing. The initial cash consideration of $6.28 per share of common stock represents a premium of approximately 49.5% to Lifecore's closing price on September 25, 2026, the last full trading day prior to signing the merger agreement. Assuming full CVR performance milestone payments of $160 million, the aggregate potential merger consideration of $9.67 per share of common stock or common stock equivalent represents a premium of approximately 130.2% to Lifecore's closing price on September 25, 2026, the last full trading day prior to signing the merger agreement.
Lifecore Biomedical Trading Halted, News Pending
Lifecore Biomedical trading halted, news pending
Artículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.